ONT 10

Drug Profile

ONT 10

Alternative Names: BGLP-40; L-BGLP40

Latest Information Update: 20 Nov 2015

Price : $50

At a glance

  • Originator Biomira
  • Developer Celldex Therapeutics Inc; Oncothyreon
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Breast cancer; Ovarian cancer; Solid tumours

Most Recent Events

  • 05 Nov 2015 Discontinued - Phase-I for Solid tumours (Second-line therapy or greater) in USA (SC)
  • 05 Nov 2015 Discontinued - Phase-I for Ovarian cancer (Combination therapy, Late-stage disease) in USA (SC)
  • 05 Nov 2015 Discontinued - Phase-I for Breast cancer (Combination therapy, Late-stage disease) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top